Libenzapril (BioDeep_00000772186)
代谢物信息卡片
化学式: C18H25N3O5 (363.1794)
中文名称: 赖苯普利
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: C1CC2=CC=CC=C2N(C(=O)C1NC(CCCCN)C(=O)O)CC(=O)O
InChI: InChI=1S/C18H25N3O5/c19-10-4-3-6-14(18(25)26)20-13-9-8-12-5-1-2-7-15(12)21(17(13)24)11-16(22)23/h1-2,5,7,13-14,20H,3-4,6,8-11,19H2,(H,22,23)(H,25,26)/t13-,14-/m0/s1
描述信息
D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors > D000806 - Angiotensin-Converting Enzyme Inhibitors
C78274 - Agent Affecting Cardiovascular System > C270 - Antihypertensive Agent
C471 - Enzyme Inhibitor > C783 - Protease Inhibitor > C247 - ACE Inhibitor
D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents
同义名列表
1 个代谢物同义名
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
| 亚细胞结构定位 | 关联基因列表 |
|---|
文献列表
- J M Morgan, A J Piraino, S D Saris, C S Graham, W L Hirschhorn, G M Kochak, R L Choi. Inhibition of angiotensin-converting enzyme with libenzapril in normotensive males.
Journal of clinical pharmacology.
1994 Dec; 34(12):1177-82. doi:
10.1002/j.1552-4604.1994.tb04729.x. [PMID: 7738213] - J S Kim, R L Oberle, D A Krummel, J B Dressman, D Fleisher. Absorption of ACE inhibitors from small intestine and colon.
Journal of pharmaceutical sciences.
1994 Sep; 83(9):1350-6. doi:
10.1002/jps.2600830929. [PMID: 7830254] - G B Weiss, B Sturm, N R Levens. Rapid reversal of angiotensin I-induced contractions in rat carotid arteries after acute and chronic treatment with the angiotensin-converting enzyme inhibitor, 3-[(5-amino-1-carboxy-1S-pentyl)amino]2,3,4,5-tetrahydro-2-oxo- 3S-1H-1-benzazepena-1-acetic acid (CGS 16617).
The Journal of pharmacology and experimental therapeutics.
1993 Dec; 267(3):1407-13. doi:
NULL. [PMID: 8263802] - Y Tsuji, D A Goldfarb, Z Masaki, C M Ferrario. Patterns of renal function in hypertension due to unilateral renal artery occlusion.
Clinical and experimental hypertension. Part A, Theory and practice.
1992; 14(6):1067-81. doi:
10.3109/10641969209038193. [PMID: 1358485] - D Gaudry, M Hayes, L Khemani, J Miotto, D Alkalay. Determination of CGS 16617 and stable isotope-labeled CGS 16617, an angiotensin-converting enzyme inhibitor, in human plasma by gas chromatography/mass spectrometry.
Biological mass spectrometry.
1991 Jan; 20(1):26-30. doi:
10.1002/bms.1200200107. [PMID: 1883857] - E M Grieve, G M Hawksworth, J G Simpson, P H Whiting. Effect of thromboxane synthetase inhibition and angiotensin converting enzyme inhibition on acute cyclosporin A nephrotoxicity.
Biochemical pharmacology.
1990 Nov; 40(10):2323-9. doi:
10.1016/0006-2952(90)90729-5. [PMID: 2244933] - G M Kochak, R L Choi, J K deSilva, P Reydel-Bax. Pharmacodynamic dependent disposition of the angiotensin converting enzyme inhibitor, libenzapril.
Journal of clinical pharmacology.
1990 Feb; 30(2):138-43. doi:
10.1002/j.1552-4604.1990.tb03452.x. [PMID: 2312764] - H Egger, G Kochak, P Robertson, R Iannucci, F A Rufino, F Stancato. Physiological disposition of CGS 16617 in rat, dog, and man.
Drug metabolism and disposition: the biological fate of chemicals.
1989 Nov; 17(6):669-72. doi:
NULL. [PMID: 2575505] - N R Levens, G M Ksander, M B Zimmerman, K M Mullane. Thromboxane synthase inhibition enhances action of converting enzyme inhibitors.
Hypertension (Dallas, Tex. : 1979).
1989 Jan; 13(1):51-62. doi:
10.1161/01.hyp.13.1.51. [PMID: 2910814] - G Waeber, M Burnier, M Porchet, J Nussberger, B Waeber, H R Brunner. Effects of prolonged administration of the angiotensin converting enzyme inhibitor CGS 16617 in normotensive volunteers.
European journal of clinical pharmacology.
1989; 36(6):587-91. doi:
10.1007/bf00637741. [PMID: 2550244] - R L Choi, G M Kochak, P Reydel-Bax, E B Nelson. Effects of food on the bioavailability of CGS 16617, an angiotensin-converting enzyme inhibitor, in healthy subjects.
Journal of clinical pharmacology.
1988 Sep; 28(9):848-52. doi:
10.1002/j.1552-4604.1988.tb03227.x. [PMID: 3230152] - N R Levens. Renal actions of the new angiotensin converting enzyme inhibitor CGS 16617.
Archives internationales de pharmacodynamie et de therapie.
1988 Mar; 292(?):266-80. doi:
NULL. [PMID: 2840040] - H Bitterman, G R Phillips, G Dragon, A M Lefer. Potentiation of the protective effects of a converting enzyme inhibitor and a thromboxane synthetase inhibitor in hemorrhagic shock.
The Journal of pharmacology and experimental therapeutics.
1987 Jul; 242(1):8-14. doi:
NULL. [PMID: 3039116] - P Reydel-Bax, E Redalieu, A Rakhit. Direct determination of angiotensin-converting enzyme inhibitors in plasma by radioenzymatic assay.
Clinical chemistry.
1987 Apr; 33(4):549-53. doi:
10.1093/clinchem/33.4.549. [PMID: 3030582]
